TerminatedPhase 2

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Stopped: Low accrual rate

South Korea6 participantsStarted 2014-04

Plain-language summary

Alveolar soft part sarcoma (ASPS), a rare subset of STS (\<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Measurable lesion defined by RECIST v1.1 * Chemo-naïve or prior chemotherapies * Adequate organ function Exclusion Criteria: * Prior malignancies * Active CNS disease * High-risk for gastrointestinal bleeding * Significant cardiovascular disease * Uncontrolled hypertension * Bleeding diathesis

What they're measuring

Overall response rate (ORR)

Timeframe: One year

Trial details

NCT IDNCT02113826

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-09

View on ClinicalTrials.gov More Metastatic Alveolar Soft Part Sarcoma trials